Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 16.90% |
| A M R CP | AAMRQ | 7.72% |
| JAZZ PHARMAC | JAZZ | 6.97% |
| SANTARUS INC | SNTS | 6.50% |
| OLD SECOND B | OSBC | 5.64% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Cymer Inc. ( CYMI - Snapshot Report ) has reported first quarter 2012 earnings of 68 cents per share, strongly beating the Zacks Consensus Estimate of 24 cents on a favorable tax rate.
Revenue
Cymer reported revenue of $150.5 million in the first quarter, down 2.5% from $154.4 million in the year-ago period. However, revenue surpassed the Zacks Consensus Estimate of $139.0 million, thanks to customer acceptance on the three extreme ultraviolet (EUV) 3100 sources and strong demand for deep ultraviolet (DUV) light sources. OnPulse revenue was strong driven by the mix of higher value ArF pulses and installed base growth.
In the quarter, the company shipped 26 DUV light sources, of which 17 were ArF immersion and 9 were KrF, and the company installed 47 DUV light sources at chipmaker locations.
Bookings
In the reported quarter, DUV and Installed Base Products’ (IBP) bookings totaled $135.8 million, leaving Cymer with a book-to-bill ratio of 1.06, reflecting strong growth in 2012. The company ended the quarter with a DUV backlog of approximately $56.2 million.
Operating Results
The reported gross profit decreased 5.0% year over year to $75.5 million. Gross margin decreased 130 basis points from the year-ago quarter to 50.2% due to weak revenue.
Operating income came in at $16.7 million, up 53.2% year over year. Operating margin decreased 1,200 basis points year over year to 53.2%. R&D and S&M expenses increased as a percentage of sales, as did SG&A expenses. Lower gross margins also led to the decline in the quarter’s operating margin.
Reported net income was $21.5 million or 68 cents per share, down from $28.8 million or 94 cents in the comparable quarter last year.
Balance Sheet & Cash Flow
Cymer exited the first quarter with cash, cash equivalents, restricted cash and short-term investments of approximately $2.7 billion, up from $2.6 billion in the prior quarter. Trade receivables were $126.9 million, up from $124.0 million in the prior quarter.
Cash flow from operations was $31.6 million, up from $12.1 million in the previous quarter. Capital expenditure increased to $9.3 million from $4.3 million in the prior quarter.
Guidance
For the second quarter of 2012, Cymer expects total revenue of approximately $151 million. Gross margin is expected to be 50%, R&D expenses of $58 million, SG&A expenses of $16.5 million, and an effective tax rate of 0%.
Our Take
Cymer is the world's leading supplier of light sources, which are contained within excimer laser-based photolithography systems. The first quarter was lackluster, with both revenue and earnings lagging prior-year figures. However, the revenue and earnings numbers were above the Zacks Consensus Estimates.
Cymer holds 80% share of the entire installed base of DUV lithography tools and is well positioned for growth in the long term. The company continues to expand installed base product offering by introducing new advanced performance enhancements and data offerings to OnPulse customers. We also remain encouraged by the strong bookings growth in the first quarter and expect strong recovery in the coming quarters.
Currently, Cymer has only one DUV light source competitor, Gigaphoton. Gigaphoton is a wholly owned subsidiary of Komatsu Ltd. ( KMTUY ) and is headquartered in Japan. In the development of EUV source technology, the company faces competition from Gigaphoton as well as Ushio.
Currently, Cymer has a Zacks #3 Rank, implying a short-term Hold recommendation.
Read the full Snapshot Report on CYMI
Read the full on KMTUY